Avalo Therapeutics (AVTX) EBITDA Margin (2016 - 2025)
Avalo Therapeutics' (AVTX) quarterly EBITDA Margin came in at 33461.02% in Q4 2025, down 2652820.0% YoY from N/an in Q4 2024, and down 382.65% on a QoQ basis from 6932.81% in Q4 2024.
Powered by 
Analysis
Avalo Therapeutics (AVTX) EBITDA Margin (2016 - 2025) Analysis & Trends
Avalo Therapeutics (AVTX) has 10 years of EBITDA Margin data on file, last reported at 33461.02% in Q4 2025.
- Quarterly EBITDA Margin fell 2652820.0% year-over-year to 33461.02% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 14585.0% (up 95105.0% YoY) and the FY2025 annual result came in at 123601.69%, down 10806609.0% from the prior year.
- EBITDA Margin eased to 33461.02% in Q4 2025, from 6932.81% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 27.39% in Q3 2022 to a low of 33461.02% in Q4 2025.
- A 5-year average of 4782.2% and a median of 1588.98% in 2023 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2022 — EBITDA Margin jumped 721400 bps — and 2025, when it slumped 2652820 bps.
- Tracing AVTX's EBITDA Margin over 5 years: stood at 8202.28% in 2021, then soared by 88 bps to 988.28% in 2022, then tumbled by 36 bps to 1341.16% in 2023, then slumped by 417 bps to 6932.81% in 2024, then sank by 383 bps to 33461.02% in 2025.
- The last three EBITDA Margin figures came in at 33461.02% (Q4 2025), 6932.81% (Q4 2024), and 5165.06% (Q3 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Avalo Therapeutics | 843.26 Mn | 843.26 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -33,461.02% |
| Dec 31, 2024 | -6,932.81% |
| Sep 30, 2024 | -5,165.06% |
| Dec 31, 2023 | -1,341.16% |
| Sep 30, 2023 | -1,588.98% |
| Jun 30, 2023 | -1,111.98% |
| Mar 31, 2023 | -1,850.95% |
| Dec 31, 2022 | -988.28% |
| Sep 30, 2022 | 27.39% |
| Jun 30, 2022 | -1,145.01% |
| Mar 31, 2022 | -1,777.75% |
| Dec 31, 2021 | -8,202.28% |
| Sep 30, 2021 | -1,219.48% |
| Jun 30, 2021 | -510.55% |
| Mar 31, 2021 | -6,465.12% |
| Dec 31, 2020 | -1,091.45% |
| Sep 30, 2020 | -1,195.05% |
| Jun 30, 2020 | -883.03% |
| Mar 31, 2020 | -1,140.63% |
| Dec 31, 2019 | -985.32% |